Nichole
Garcia

Most founders enter a market they've studied from the outside. Nichole Garcia entered hers from the inside, with two decades of scar tissue from the companies she helped build. She ran Philips' professional oral healthcare division as President. She was General Manager at Align Technology - the parent company of Invisalign, the product that invented the clear aligner category. She had watched, up close, how the industry priced out millions of patients who needed teeth straightening and couldn't afford the friction.

So in 2017, with two Invisalign insiders - Ren Menon (formerly head of global product management) and Henry Chan (formerly director of R&D) - Garcia co-founded OrthoFX. The founding team knew the product, the supply chain, the clinical protocols, and the market gaps with uncommon precision. Their company wouldn't be a bet on a new category. It would be a correction of an old one.

The insight behind OrthoFX wasn't just about cost. It was about architecture. The industry had bifurcated: legacy players (Invisalign at the premium end) required lots of in-office visits and charged accordingly. Challenger brands went fully direct-to-consumer but removed the doctor entirely - and got burned by patient safety issues and regulatory scrutiny. Garcia and her co-founders saw the gap: a model that was doctor-delivered but digitally managed, accessible in price but uncompromising in clinical quality.

The technical execution of that insight is OrthoFX's FXTetra polymer - a proprietary material Garcia's team developed that nobody else in the market has access to. FXTetra aligners apply more consistent, gentle force than traditional aligner materials, which translates to faster treatment timelines (50% faster than competitors, according to OrthoFX's clinical data) and dramatically fewer mid-course corrections. When 80% of your treatments end without any refinements needed, the economics of the whole model change.

Patients who've worn OrthoFX aligners have a name for them: the "Tempur-Pedic of teeth." The comparison isn't just flattery - it points at something real. The FXTetra polymer is hyperelastic in a way that standard aligner materials aren't. It deforms gently under load, applies continuous but measured force, and returns to its original shape without fatiguing the material. For patients, this means less discomfort and shorter daily wear requirements. For clinicians, it means more predictable tooth movement.

The other half of OrthoFX's product story is software. FXOnTrack AI is the company's remote treatment management platform - a digital layer that sits between the patient's smartphone and their doctor's dashboard. Patients submit check-in photos through the app; the AI analyzes tooth movement progress; doctors review flagged cases and approve next steps. The result is a system where most treatment decisions happen remotely, most visits are optional, and most courses end on time without intervention.

The product architecture reflects Garcia's commercial instincts: give patients options that fit their lives, price them with transparency, and give doctors a platform that makes professional oversight scalable. The company's stated goal has always been to bring doctor-supervised orthodontic care to the millions of people who currently choose between too-expensive traditional treatment and no treatment at all.

Garcia's career looks like a directed march through every layer of the oral care industry, accumulating domain knowledge at each stop that would eventually fuse into OrthoFX. The starting point was biochemistry - a UCLA undergraduate degree that gave her a molecular-level understanding of materials that would later inform her company's core innovation.

After graduating in 1996, she moved into global commercial roles, not research - a signal of where her instincts ran. She spent the next two decades building and running international divisions, managing P&Ls, leading M&A processes, and scaling companies across the consumer health and dental sectors. By the time she joined Philips Oral Care, she was running the company's global professional division. By the time she joined Align Technology, she had the background of a company builder, not just a manager.

The Oxford detour is worth noting. Between 2008 and 2010, while running commercial operations at Discus Dental and preparing to join Philips, Garcia studied Corporate Finance, Banking, and Securities Law at Oxford. It's the kind of credential that doesn't fit neatly into a standard healthcare executive biography - and that's probably the point. Garcia has always combined the analytical instincts of a scientist with the commercial range of a deal-maker.

Garcia's academic credentials span biochemistry, business strategy, and financial law - a combination that maps almost perfectly onto what it takes to build a medical device company from the ground up: understanding the science, commanding the market, and structuring the capital.

OrthoFX was incorporated in 2017 and launched its first commercial product in June 2019 - two years of R&D before a single aligner reached a patient's mouth. The company is headquartered in Fremont, California, with Garcia based in San Francisco. By the time SignalFire led the $13M Series A in July 2020, OrthoFX had already demonstrated product-market fit during one of the most disruptive periods in the history of dental practice: the COVID-19 pandemic. OrthoFX reported record sales growth in 2020 precisely because its remote-first model worked when clinics couldn't operate normally.

The company now employs around 130 people and reports approximately $17.9M in annual revenue. The founding team's unique combination - a CEO with product management depth, a CTO with R&D credentials, and a President with global commercial experience - gave OrthoFX a rare functional completeness from day one. Most startups hire commercial leadership late. OrthoFX had one at the founding table.

Garcia's particular value as a founder comes from a quality that is hard to fake: she has been, in sequence, a scientist, a marketer, an operations executive, a financial analyst, and a company builder. Each identity overlaps with the next in ways that make her unusually hard to categorize - and unusually effective at solving problems that require multiple frames at once.

The OrthoFX founding story is really a story about what insider knowledge looks like when it's directed outward. Garcia didn't just know that the legacy orthodontic model was flawed; she knew precisely which levers controlled the costs, which clinical protocols were over-engineered, and which parts of the patient journey created unnecessary friction. Building a better system wasn't speculation - it was an engineering problem she was already holding the blueprint for.

The doctor-delivered D2C model that OrthoFX pioneered is Garcia's signature contribution to the category. It resists easy classification: it's not fully DTC (there's a doctor in the loop at every step) and it's not traditional clinical (patients rarely need to come in after their initial scan). The model works because it was designed by someone who understood the clinical, commercial, and regulatory constraints simultaneously - and found the narrow pass between them.